De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
GlaxoSmithKline Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Bhushan Akshikar
Algemeen directeur
₹66.9m
Totale compensatie
| Percentage CEO-salaris | 21.7% |
| Dienstverband CEO | 1.8yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 2yrs |
| Gemiddelde ambtstermijn bestuur | 6.5yrs |
Recente managementupdates
Recent updates
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%
Jun 01With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case
May 05GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear
Apr 14Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?
Jan 18GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected
Dec 28Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today
Oct 05Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On
Mar 20Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?
Feb 27Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?
Feb 06What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?
Jan 11
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain
Dec 06Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts
Nov 01Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield
Oct 29What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?
Sep 29If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today
Aug 30Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?
Aug 02It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend
Jul 12Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?
Jul 07Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹6b |
| Mar 31 2024 | ₹67m | ₹15m | ₹6b |
| Dec 31 2023 | n/a | n/a | ₹5b |
| Sep 30 2023 | n/a | n/a | ₹6b |
| Jun 30 2023 | n/a | n/a | ₹6b |
| Mar 31 2023 | ₹34m | ₹4m | ₹6b |
Compensatie versus markt: De totale vergoeding ($USD 797.94K ) Bhushan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 637.49K ).
Compensatie versus inkomsten: De vergoeding van Bhushan is het afgelopen jaar met meer dan 20% gestegen.
CEO
Bhushan Akshikar
1.8yrs
Tenure
₹66,885,000
Compensatie
Mr. Bhushan Akshikar is Managing Director of GlaxoSmithKline Pharmaceuticals Limited from December 1, 2022. He served as Additional Director of GlaxoSmithKline Pharmaceuticals Limited since March 18, 2021...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Executive Director | 1.8yrs | ₹66.89m | geen gegevens | |
| Whole-Time Director & CFO | 2.5yrs | ₹68.92m | geen gegevens | |
| Executive Vice President of Human Resources | 3.8yrs | ₹37.40m | geen gegevens | |
| Vice President of Technology | less than a year | geen gegevens | geen gegevens | |
| VP of Administration & Real Estate and Company Secretary | no data | ₹11.57m | geen gegevens | |
| Executive Vice President of Legal | 2.7yrs | geen gegevens | geen gegevens | |
| Vice President of Ethics & Compliance | 1.7yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Communications & Government Affairs | 7.5yrs | geen gegevens | geen gegevens | |
| Executive Vice-President of Regulatory Affairs | no data | geen gegevens | geen gegevens | |
| Executive Vice-President of Adult Vaccines | 2.3yrs | geen gegevens | geen gegevens | |
| Executive Vice President of General Medicines | 1.8yrs | geen gegevens | geen gegevens | |
| Commercial Head - Paediatric Vaccines | 1.8yrs | geen gegevens | geen gegevens |
2.0yrs
Gemiddelde duur
Ervaren management: Het managementteam van GLAXO wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD & Executive Director | no data | ₹66.89m | geen gegevens | |
| Whole-Time Director & CFO | 2.5yrs | ₹68.92m | geen gegevens | |
| Non-Executive Chairperson | 5.5yrs | ₹3.25m | geen gegevens | |
| Independent Director | 2.4yrs | ₹2.65m | geen gegevens | |
| Non-Executive Independent Director | 15.3yrs | ₹2.70m | geen gegevens | |
| Non Executive Director | 7.5yrs | geen gegevens | geen gegevens | |
| Non-Executive Independent Director | 14yrs | ₹2.70m | geen gegevens | |
| Non-Executive Independent Director | 12.9yrs | ₹2.45m | geen gegevens | |
| Non-Executive & Independent Director | 4.4yrs | ₹2.45m | geen gegevens |
6.5yrs
Gemiddelde duur
68.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van GLAXO wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.5 jaar).